IL13RA2 and glioblastoma: Typical targets for CAR-T cell therapy in GBM, such as IL-13Rα2 and EGFRvIII, are heterogeneously expressed at both the inter- and intrapatient levels and can fluctuate in a spatial and temporal manner [75].